Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Cogent Biosciences (Nasdaq: COGT), a biotechnology company specializing in precision therapies for genetically defined diseases, announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Andrew Robbins, President and CEO, will deliver a presentation on Tuesday, January 14, 2025, at 7:30 a.m. PT/10:30 a.m. ET. The presentation will be accessible via live webcast on the company's Investors & Media webpage, with a replay available for 30 days following the event.

WALTHAM, Mass. and BOULDER, Colo., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer, will present at the 43^rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025 at 7:30 a.m. PT/10:30 a.m. ET.

A live webcast will be available on the Investors & Media page of Cogent’s website at investors.cogentbio.com. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days.

About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition to bezuclastinib, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2, PI3Kα and KRAS. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: X (formerly known as Twitter) and LinkedIn. Information that may be important to investors will be routinely posted on our website and X.

Contact:
Christi Waarich
Senior Director, Investor Relations
christi.waarich@cogentbio.com
617-830-1653

FAQ

When is Cogent Biosciences (COGT) presenting at the 2025 J.P. Morgan Healthcare Conference?

Cogent Biosciences will present on Tuesday, January 14, 2025, at 7:30 a.m. PT/10:30 a.m. ET.

How can investors watch COGT's presentation at the J.P. Morgan Healthcare Conference?

Investors can watch the presentation via live webcast on Cogent's website at investors.cogentbio.com. A replay will be available for 30 days after the event.

Who will represent COGT at the 2025 J.P. Morgan Healthcare Conference?

Andrew Robbins, President and Chief Executive Officer of Cogent Biosciences, will present at the conference.

How long will COGT's J.P. Morgan Healthcare Conference presentation replay be available?

The presentation replay will be archived and available for up to 30 days after the event.